Figure 1.

 Combining kallistatin gene therapy and meloxicam shows a stronger effect in suppressing tumor growth compared to monotherapies. HepG2 hepatomas were established. When the tumors reached approximately 100 mm³ (indicated by a vertical arrow), they received pcDNA3.1 (control), Kalli‐pcDNA3.1, meloxicam, or Kalli‐pcDNA3.1 + meloxicam treatments. The sizes (mm³) of tumors were recorded. †Significant difference in tumor volumes compared to control. Significant difference in tumor volumes compared to Kalli‐pcDNA3.1 treatment (‡), and meloxicam treatment (§).